Industry: Cannabis
Cannabis funding and investors
Growers, dispensaries and multi-state operators now raise mostly from lenders and property buyers, not venture funds. We prepare the deck, model and lender materials that hold up in their credit reviews.
- Equity, loans and sale-leasebacks, compared for your licences and states
- Decks and models that show cash flow after 280E and debt service
- Waveup prepares investor materials for cannabis companies: $3B+ raised for 600+ startups since 2014
In short
What is cannabis funding?
Cannabis funding is the money licensed growers, dispensaries and multi-state operators raise to build, buy and refinance. Most of it is debt: loans, notes and sale-leasebacks of their buildings. Debt made up 61% of the cannabis deal value Viridian tracked from January to September 2026. Equity is scarce, so lenders set the terms.
- Who it's for
- Cultivators, dispensaries, multi-state operators and ancillary companies, pre-seed to Series D+
- What we build
- Investor and lender deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Why is the cannabis industry struggling to raise money?
Prices keep falling in older markets, and adult-use sellers still can't deduct normal costs for federal tax. Yet operators with steady cash flow still find lenders and property buyers.
The opportunity
Federal rules began to shift in 2026, and consolidators are buying licensed stores.
- Medical marijuana under a state licence moved to Schedule III in April 2026
- Consolidators are buying stores, paying with shares and seller notes
- REITs and private lenders still fund operators with steady cash flow
The problem
Equity has nearly dried up: cannabis companies raised $142M of it from January to September 2026. Lenders fill the gap, and they want security, covenants and steady cash flow.
Market size
How much cannabis do licensed US stores sell, and what's changing?
Licensed US stores sold about $27 billion of cannabis in 2025, by The Marijuana Herald's tally of state reports. Four shifts decide who gets funded next:
- Rescheduling: state-licensed medical marijuana entered Schedule III on 28 April 2026, and a wider DEA decision is pending
- Price pressure: adult-use flower in Michigan averaged $61.91 an ounce at retail in October 2025
- Consolidation: Cresco Labs agreed to buy nine PharmaCann stores in Pennsylvania in 2026
- New taxes: Michigan added a 24% wholesale tax on adult-use marijuana from 1 January 2026
Venture capital
Where does cannabis capital come from in 2026?
Cannabis deal value rose in 2026, but most of it was debt and M&A rather than new equity. Deals also got smaller as the year went on.
in cannabis debt, equity and M&A deals from January to September 2026
average cannabis deal in Q3 2026, down from about $41M in Q1
M&A deals in Q3 2026, the most common deal type that quarter
Who invests in cannabis companies?
A cannabis-led equity investor, specialist lenders and sale-leaseback REITs, with a few names for each. Equity is the scarcest of the three.
Investor database
Pharma investors in our database
The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by pharma investments
Investments by industry
- Healthtech & Wellness42%
- Pharma19%
- Biotech17%
- Rounds
- Pre-seedSeed
- Average cheque
- Not listed
- Based in
- Los Angeles, California, United States
28 investments in total, 7 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness40%
- Software & Apps15%
- Pharma7%
- Rounds
- Pre-seedSeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Dallas, United States
- Invests in
- USA
88 investments in total, 7 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness49%
- Biotech20%
- Pharma14%
- Rounds
- SeedSeries A
- Average cheque
- Not listed
- Based in
- Toronto, Ontario, Canada
25 investments in total, 5 tagged Pharma.Open the full fund profile
Investments by industry
- Biotech21%
- Healthtech & Wellness19%
- Hardware. Robotics & IoT17%
- Pharma7%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $1M–$3M$3M–$10M
- Based in
- Jackson, United States
- Invests in
- USA
62 investments in total, 3 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness50%
- Biotech19%
- Pharma6%
- Rounds
- Seed
- Average cheque
- Not listed
- Based in
- San Francisco, United States
- Invests in
- Europe, USA, Canada
33 investments in total, 2 tagged Pharma.Open the full fund profile
From our investor database.
Where do cannabis raises get stuck?
We interviewed 56 VCs for our Fundraising 2025 study. Their top reasons to pass were revenue growth, unit economics, burn and missed milestones. Defensibility and crowded categories came next. Cannabis lenders and investors start with four questions of their own.
Federal tax on adult-use sales
Adult-use marijuana is still in Schedule I, so section 280E still blocks normal deductions on those sales. For registered medical licensees, the April 2026 rule says 280E no longer applies.
What investors ask
- What's your cash tax bill on adult-use sales, and on medical sales since April 2026?
What your deck shows
- Cash taxes by line of business, before and after rescheduling
- Any open tax positions, and what you've reserved for them
Banks that won't lend
FinCEN counted 507 banks serving marijuana businesses at the end of 2024. Few make large loans, so operators borrow from private lenders on tighter terms.
What investors ask
- Who lends to you today, at what rate, and when does it mature?
What your deck shows
- A debt schedule with rates, covenants and maturities
- Cash flow that covers interest, with room to spare
Prices that keep falling
Colorado's legal cannabis sales in 2025 were 41% below their 2021 peak. Older markets reward low-cost growers and well-placed stores.
What investors ask
- What's your margin if wholesale prices drop again next year?
What your deck shows
- Cost per pound against today's wholesale price
- Sales per store and average basket, month by month
Debt that comes due
In 2026, lender SNDL foreclosed on Parallel's stores, extinguishing about $842M of debt. Lenders take control when cash flow can't carry the loans.
What investors ask
- How will you refinance before your notes mature?
What your deck shows
- A maturity schedule and the cash flow that meets it
- Owned property that could fund a sale-leaseback
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Your case for lenders or investors, built on cash flow after tax.
280E, rescheduling scenarios and debt service, month by month.
A range grounded in recent cannabis store and licence deals.
Cannabis funds, private lenders and REITs that fit your stage.
Licences, leases, tax filings and compliance records, in order.
For selling stores to a consolidator, or an extended CIM for lenders.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups.
About usCannabis funding FAQ
How do cannabis businesses get funding?
Who are the biggest cannabis investors?
Can a cannabis business get a bank loan?
What is a cannabis sale-leaseback?
What does rescheduling mean for cannabis funding?
How much does help with a cannabis raise cost?
Raising for a cannabis company?
Tell us your states, licences and how much you need. We'll map the lenders and investors who fit, and what each will check.





